Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...

Edwards Lifesciences (NYSE:EW) traded higher on Thursday after Stifel upgraded the heart device maker to Buy from Hold, citing a turnaround in its position in the market for transcatheter aortic valve ...

Transcatheter aortic valve replacement (TAVR) is valve replacement without open-heart surgery. It is also called catheter-based or percutaneous (through the skin) aortic valve replacement. While ...

Whether transcatheter aortic-valve replacement can improve outcomes in patients with asymptomatic severe aortic stenosis has been unclear. New research findings comparing TAVR with clinical ...

while 100,000 patients die annually due to lack of treatment. Although TAVR market growth has slowed, the analyst sees the market as underpenetrated and views it as a promising target for the next ...

With its potential to improve clinical outcomes for a broader range of patients, the JenaValve Trilogy System underscores the growing adaptability of TAVR technology in treating complex heart ...

Since initial FDA approval in 2011, TAVR has revolutionized ... faculty who come together and review all data to bring about the best outcome in each and every patient,” says Olcay Aksoy ...

(European Heart Journal) A randomized trial in China showed that a pharmacist-led management model improved medication adherence among patients ... after transcatheter aortic valve replacement ...